BRCA1 and neoplasm: First, we built a cohort of 63 patients with TNBC (including 32 BRCA1-wildtype and 31 BRCA1-mutant tumor samples) and optimized an immunohistochemistry assay to evaluate nuclear vs. cytoplasmic ADAR1p150 expression in tumor cells.